AbbVie
ABBV
$162.73
Share price
-0.65%
Change (1 day)
10.36%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Market capitalization of AbbVie (ABBV)
Market cap: $289.23 Billion
As of May 2024 AbbVie has a market cap of $289.23 Billion. This makes AbbVie the world's 34th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of AbbVie from 2012 to 2024
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2024 | $289.23 B | 5.71% |
| 2023 | $273.60 B | -4.27% |
| 2022 | $285.80 B | 19.4% |
| 2021 | $239.37 B | 26.54% |
| 2020 | $189.17 B | 44.47% |
| 2019 | $130.94 B | -3.95% |
| 2018 | $136.33 B | -11.7% |
| 2017 | $154.39 B | 51.71% |
| 2016 | $101.76 B | 6.7% |
| 2015 | $95.37 B | -8.42% |
| 2014 | $104.14 B | 24.23% |
| 2013 | $83.82 B | 55.32% |
| 2012 | $53.97 B |
End of Day market cap according to different sources
On May 6th, 2024 the market cap of AbbVie was reported to be:
$288.13 Billion
$288.13 Billion
$288.13 Billion
$287.45 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $159.45 B | -44.87% | 🇺🇸 USA |
 Eli Lilly LLY | $728.65 B | 151.93% | 🇺🇸 USA |
 Amgen AMGN | $166.94 B | -42.28% | 🇺🇸 USA |
 Biogen BIIB | $32.23 B | -88.85% | 🇺🇸 USA |
 Gilead Sciences GILD | $81.72 B | -71.74% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $89.17 B | -69.17% | 🇺🇸 USA |
 AstraZeneca AZN | $234.89 B | -18.79% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $88.59 B | -69.37% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $14.26 B | -95.07% | 🇺🇸 USA |